5-1-2020

Section:

Serum Hepcidin In Patients With Chronic Hepatitis C And Its Relation To Treatment With Antiviral Drugs

Mohamed Ali  
*Clinical Pathology Department, Faculty of Medicine, Al-azhar university, Cairo, Egypt,*  
mohamad.khamis14@gmail.com

Ashraf Sayed  
*Clinical Pathology Department, Faculty of Medicine, Al-azhar University, Cairo, Egypt,*  
asrash.a.monem11@gmail.com

Mostafa Elhawary  
*Department of Tropical Medicine, Faculty of Medicine, Al-azhar University, Cairo, Egypt,*  
mostafahawary22@yahoo.com

Ahmed Assem  
*Clinical Pathology Department, Faculty of Medicine, Al-azhar University, Cairo, Egypt,*  
ahmedassem78@yahoo.com

Follow this and additional works at: [https://aimj.researchcommons.org/journal](https://aimj.researchcommons.org/journal)

Part of the Medical Sciences Commons, Obstetrics and Gynecology Commons, and the Surgery Commons

How to Cite This Article  
Ali, Mohamed; Sayed, Ashraf; Elhawary, Mostafa; and Assem, Ahmed (2020) "Serum Hepcidin In Patients With Chronic Hepatitis C And Its Relation To Treatment With Antiviral Drugs," *Al-Azhar International Medical Journal* Vol. 1: Iss. 5, Article 4.  
DOI: [https://doi.org/10.21608/aimj.2020.28247.1201](https://doi.org/10.21608/aimj.2020.28247.1201)

This Original Article is brought to you for free and open access by Al-Azhar International Medical Journal. It has been accepted for inclusion in Al-Azhar International Medical Journal by an authorized editor of Al-Azhar International Medical Journal. For more information, please contact dryasserhelmy@gmail.com.
Serum Hepcidin in Patients with Chronic Hepatitis C and its Relation to Treatment with Antiviral Drugs


*Corresponding Author: Mohamed Khamis Ali Khalil mohamad.khamis14@gmail.com

Received for publication April 19, 2020; Accepted June 30, 2020; Published online June 30, 2020.

Copyright 2020 The Authors published by Al-Azhar University, Faculty of Medicine, Cairo, Egypt. All rights reserved. This an open-access article distributed under the legal terms, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

1Clinical Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

2 Tropical Medicine Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

ABSTRACT

Background: There is a relationship between HCV infection and accumulation of body iron in the liver. Iron overload has been found to be cofactor for HCV associated fibrosis and hepatocellular carcinoma. Hepcidin produced by hepatocytes, is very important in regulation of iron metabolism. Disturbances in Hepcidin concentrations have been reported in chronic HCV infection and hepatocellular carcinoma. The aim of the work: is to measure levels of serum hepcidin in chronic hepatitis C patients and evaluate any association with the viral load after antiviral treatment. 

Aim of work: To measure hepcidin level in chronic hepatitis C patients (before and after treatment with antiviral drugs) and healthy controls to assess the level of hepcidin in CHC and its relation to antiviral therapy.

Patient and methods: Our study was carried on 50 patients with chronic hepatitis C. Hepcidin levels were evaluated for Hepcidin before starting the antiviral therapy treatment (group A) and after 24 weeks course of antiviral therapy (group B) with a commercially available enzyme-linked immunosorbent assay kits in addition to 20 apparently normal volunteers with matched age and sex as control group (group C).

Results: Regarding serum Hepcidin, there was a highly statistical significant difference between patient and control group. Hepcidin levels in CHC patients were low in comparison to HCV -ve people. Highly statistical significant (p-value > 0.05) positive correlation (r = 0.67) between Hepcidin before and after treatment in patients group.

Conclusion: Chronic HCV infection is associated with low level of serum hepcidin. That effect of HCV on hepcidin level was fully reversible after antiviral treatment.

Keywords: CHC; Hepcidin; Antiviral therapy.

INTRODUCTION

Hepatitis C virus infection is a big worldwide problem, it is estimated that more than 80 million are chronically infected globally, with 3–4 million new infections and 355,000 deaths occurring each year because of its related complications.1

It is estimated that Egypt comes first worldwide in HCV prevalence, with incidence rates at 2.4 per 1000, and an estimated average of 166,000 new cases every year, according to Centers for Disease Control and Prevention (CDC).2

Infection follows a variable course; while it is often asymptomatic, some patients develop liver fibrosis and ultimately cirrhosis, which is apparent after many years.3

Hepatitis C virus remains the leading cause of chronic liver disease, accounting for 50% to 70% of primary liver cancers.4 The incidence of chronic liver disease is increasing.5

Hepcidin was first discovered in human blood and urine samples as a bactericidal peptide and named liver expressed antimicrobial peptide (LEAP-1).6 The name ‘hepcidin’ originates from hepatocytes (hep) where it is synthesized and its antimicrobial activity (cidin). It has antibacterial (Escherichia coli, Staphylococcus aureus, ect) and antifungal activity (Aspergillusniger, Aspergillusfumigatus, ect).7

Hepcidin is a circulating peptide which is secreted from liver and excreted in urine. It causes release of iron by macrophages and hepatocytes8 It regulates serum iron level and tissue distribution of iron. It inhibits iron absorption by enterocytes in the duodenum through its binding to ferroportin and inducing its degradation.9 Theses mechanisms result in decrease of serum iron level and increased intracellular iron content.10
The discovery of hepcidin in 2000\textsuperscript{12} not only opened the way to understand its antimicrobial and metabolic role but also raised the possibility of use of hepcidin as a diagnostic and therapeutic tool in some diseases. The liver is the main iron storage organ. About third of the total body iron is store in hepatocyte, sinusoidal mesenchymal cells and reticuloendothelial cells.\textsuperscript{13} It plays an important role in iron metabolism and regulation, as transferrin and ferritin are synthesized here.\textsuperscript{14}

The aim of this cross sectional case control study was to measure hepcidin level in chronic hepatitis C patients (before and after treatment with antiviral drugs) and healthy controls to assess the level of hepcidin in CHC and its relation to antiviral therapy.

**PATIENT AND METHODS**

50 patients with chronic hepatitis C infection were attended to tropical medicine department at Al-Azhar University Hospitals in addition to 20 apparently healthy people were included in this study. Written informed consents were obtained from all participants.

Patients have been evaluated for hepcidin and Other parameter before starting the treatment and defined as (group A) and after treatment and defined as (group B) in addition to 20 apparently healthy individuals (group C).

Patient with the following criteria was included in the study: adult patients of both sexes with seropositivity of HCV Ab. We excluded patients with the following criteria from the study: hepatitis B virus infection, alcoholic liver disease, and associated HCC, HIV infection and renal failure.

All patients were subjected to History, examination and investigations including: Liver function tests (ALT - AST), Kidney function tests (Urea and Creatinine), Serum bilirubin, Hemoglobin (Hb), Liver function tests (ALT - AST), Kidney function tests (Urea and Creatinine), Serum bilirubin, Hemoglobin (Hb), Hemoglobin (Hb), and regulation, as transferrin and ferritin are synthesized here. Patients have been evaluated for hepcidin and Other parameter before starting the treatment and defined as (group A) and after treatment and defined as (group B) in addition to 20 apparently healthy people were included in this study. Written informed consents were obtained from all participants.

In both control and patient groups, 8 ml of venous blood will be withdrawn, 2 ml on EDTA for CBC and the remaining amount in plain tube will be left for clotting, then centrifuged, separated serum will be divided in 2 aliquots, one used for routine investigations and the other portion will kept frozen at -80°C until used for hepcidin assay using enzyme linked immunosorbent assay (ELISA), commercial kits Catalogue No. 95618, LOT No. 201907. Iron was measured using colorimetric method by DIALAB Autolysery, commercial kits Catalogue No. D01106, LOT No 8702/24999. Ferritin was measured using sandwich immunodetection method by iCHROMA II, commercial kits Catalogue No. CFPC-32, LOT No.FRoya64.

**Statistical analysis:**

Data will be analyzed by using statistical software SPSS 13.0. All the quantitative data will be expressed as mean ± SD, while qualitative data will be expressed as percentages. Qualitative data will be analyzed by Chi-square test or Fisher’s exact test where appropriate and quantitative data by Student’s t-test, ANOVA or Mann-Whitney’s U test. Correlation study will be done by using Spearman’s correlation coefficient test. A ‘p’ value of <0.05 will be taken as statistically significant.

**RESULTS**

The characteristics for the studied group (A) cases (30 males and 20 females) are shown in (Table 1) which showing slightly elevated AST and ALT, bilirubin in comparison to control group while CRP, kidney function tests, were within normal range. As regard serum iron, there was highly significant decreased in S. iron level in group (A) patients with a mean of (76.5 ± 9.9) in comparison to control group C with a mean of (111.5 ± 11.8).

As regard S. ferritin, there was highly significant elevation in S. Ferritin level in group (A) patients with a mean of (266.2 ± 37.3) in comparison to control group with a mean of (96.4 ± 9.4). As regard serum hepcidin, there was highly significant decrease in S. hepcidin level in group (A) patients with a mean of (30.4 ± 9.9) in comparison to control group (C) with a mean of (65 ± 12.7). (Figure 1-3)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A</th>
<th>Group C</th>
<th>Stat. test</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb(g/dl)</td>
<td>Mean ±SD</td>
<td>11.9 ± 1.5</td>
<td>T = 4.4</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>Urea(mg/dl)</td>
<td>Mean ±SD</td>
<td>29.6 ± 12.7</td>
<td>T = 1.7</td>
<td>0.082 NS</td>
</tr>
<tr>
<td>Creat(mg/dl)</td>
<td>Mean ±SD</td>
<td>0.76 ± 0.3</td>
<td>T = 0.19</td>
<td>0.839 NS</td>
</tr>
<tr>
<td>Bil. T(mg/dl)</td>
<td>Mean ±SD</td>
<td>1.18 ± 0.4</td>
<td>T = 5.02</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>SGPT(U/L)</td>
<td>Mean ±SD</td>
<td>50.4 ± 13.6</td>
<td>T = 7.5</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>SGOT(U/L)</td>
<td>Mean ±SD</td>
<td>67.6 ± 25.7</td>
<td>T = 6.8</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>CRP(mg/L)</td>
<td>Mean ±SD</td>
<td>2.6 ± 1.9</td>
<td>T = 0.41</td>
<td>0.677 NS</td>
</tr>
<tr>
<td>Iron(mg/dl)</td>
<td>Mean ±SD</td>
<td>76.5 ± 9.9</td>
<td>T = 10.8</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>Ferritin(mg/l)</td>
<td>Mean ±SD</td>
<td>266.2 ± 37.3</td>
<td>T = 19.8</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>Hepcidin</td>
<td>Mean ±SD</td>
<td>30.4 ± 9.9</td>
<td>T = 10.2</td>
<td>&lt; 0.001 HS</td>
</tr>
</tbody>
</table>

T: independent sample T test. HS: p-value < 0.001 is considered highly significant. NS: p-value > 0.05 is considered non-significant.

**Table 1:** Comparison between group (A) patients & groups (C) as regard laboratory data.
To evaluate direct effect of antiviral therapy on hepcidin level, iron indices, laboratory investigations were determined in group (B) patients (after 24 weeks course of antiviral therapy) and compared with those of group (A) patients (before treatment) as shown in (Table 2, 3).

Serum hepcidin levels were significantly increased from (30.4 ± 9.9) to (95.6 ± 12.5) with P-value < 0.001 HS. Serum ferritin levels were increased from (266.2 ± 37.3) to (343.4 ± 29.3) with significant improvement of serum iron from (76.5 ± 9.9) to (100.6 ± 8.1).

Also AST and ALT were significantly decreased from (67.6 ± 25.7) and (50.4 ± 13.6) to (47.2 ± 11.7) and (38.2 ± 7.3) respectively. There was significant improvement of Hb concentration from (11.9 ± 1.5) to (12.9 ± 1.3).

### Table 2: Comparison between patients (before & after treatment) as regard laboratory data.

<table>
<thead>
<tr>
<th></th>
<th>HCV Patients</th>
<th>Stat. test</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group A</td>
<td>Group B</td>
<td></td>
</tr>
<tr>
<td>Hb(g/dl)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11.9 ± 1.5</td>
<td>12.9 ± 1.3</td>
<td>T = 2.8</td>
</tr>
<tr>
<td>Urea(mg/dl)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>29.6 ± 12.7</td>
<td>30.1 ± 9.4</td>
<td>T = 0.16</td>
</tr>
<tr>
<td>Creat(mg/dl)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.76 ± 0.3</td>
<td>0.9 ± 0.2</td>
<td>T = 1.8</td>
</tr>
<tr>
<td>Bil. T(mg/dl)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.18 ± 0.4</td>
<td>1.02 ± 0.3</td>
<td>T = 1.6</td>
</tr>
<tr>
<td>SGPT(U/L)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>50.4 ± 13.6</td>
<td>38.2 ± 7.3</td>
<td>T = 3.9</td>
</tr>
<tr>
<td>SGOT(U/L)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>67.6 ± 25.7</td>
<td>47.2 ± 11.7</td>
<td>T = 3.6</td>
</tr>
<tr>
<td>CRP(mg/L)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.6 ± 1.9</td>
<td>2.5 ± 1.1</td>
<td>T = 0.19</td>
</tr>
<tr>
<td>Iron(mg/dl)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>76.5 ± 9.9</td>
<td>100.6 ± 8.1</td>
<td>T = 9.4</td>
</tr>
<tr>
<td>Ferritin(ng/l)</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>266.2 ± 37.3</td>
<td>343.4 ± 29.3</td>
<td>T = 8.1</td>
</tr>
<tr>
<td>Hepcidin</td>
<td>Mean ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30.4 ± 9.9</td>
<td>95.6 ± 12.5</td>
<td>T = 20.3</td>
</tr>
</tbody>
</table>

T: independent sample T test. S: p-value <0.05 is considered significant. HS: p-value < 0.001 is considered highly significant. NS: p-value > 0.05 is considered non-significant.

This table shows:
- No statistical significant difference (p-value > 0.05) between patients (before & after therapy) groups regarding urea, creat, Bil T & CRP.
- Highly statistical significant difference (p-value < 0.001) between patients (before & after therapy) regarding SGPT, Iron, ferritin and hepcidin.
- Statistically significant difference (p-value < 0.05) between patients (before & after therapy) regarding Hb & SGOT.
Hepcidin is iron regulatory hormone; it is synthesized mainly in hepatocytes. Hepcidin synthesis is increased by iron overload and decreased by anemia and hypoxia. Moreover, it is also induced by infection and inflammation.

Disturbance in hepcidin regulation has been reported as a possible mechanism causing iron overload in some conditions, such as alcoholic liver disease and CHC.

Our study was conducted to estimate the level of serum hepcidin, iron and ferritin in chronic hepatitis C patients (CHC) and the effect of antiviral treatment on them. Regarding the sex distribution of the studied cases males were predominant, although patients were selected randomly. This is in agreement with the study conducted in the National Research Center, Cairo, Egypt by Moatara, this may be related to social risk factors for HCV transmission as drugs and occupational exposure.

In our study CHC patients of group (A) had elevated ALT and AST similarly; Kwo found that 43% of HCV antibody positive applicants had liver enzyme elevations less than 2 times normal. We also studied the relation between liver enzymes (ALT, AST) and baseline hepcidin levels for group (A) studied cases and we found that there was no significant correlation between hepcidin levels and liver enzymes ALT and AST.

In agreement with our results, Fujita found that there were no significant correlations between serum hepcidin levels and serum transaminase (AST and ALT).

In contrast, Tsochatzis concluded that in patients with chronic HCV, serum hepcidin correlated positively with AST and with ALT.

As regard serum iron, there was highly significant decreased in S. iron level in group (A) CHC patients in comparison to control group. These results were in agreement with Marzouk and El Lehleh who found that serum iron was decreased in CHC patients compared to control group.

Also, these results were in agreement with Fujita who found that mild anemia was a complication in CHC patients. This anemia may also affect the diminished hepatic hepcidin production in these patients.

However, these results did not agree with Mohamed who concluded that serum iron was higher in chronic hepatitis C patients in comparison to control group. These discrepancies may be because of the low number of patients and the difference in number of patient groups in stages of liver diseases.

As regard S. ferritin, there was highly significant increase in S. Ferritin in group (A) CHC patients with a mean of (266.2 ± 37.3) in comparison to control group with a mean of (96.4 ± 9.4).

Our results agreed with Oikonomou who found high serum ferritin in chronic hepatic patients which is associated with worse outcomes in patients with decompensated cirrhosis. Also Pietrangelo reported that serum ferritin was higher in CHC cirrhotic patients than controls and the levels also correlated with the severity of the disease.

### DISCUSSION

Hepatitis C virus infection is considered to be one of the main causes of chronic liver disease all over the world.

The effect of HCV infection on the liver varies from minimal changes to chronic hepatitis and cirrhosis with or without hepatocellular carcinoma. The number of chronic HCV infected cases all over the world may be approximately 177 million.

Although the main factor which causes initiation of hepatic disease processes in chronic hepatitis patients is HCV infection, it has become clear that involvement of cofactors is critical in determining the progression of this disease. Chronic HCV infection appears to be associated with iron homeostasis disturbances, with increased serum ferritin and hepatic iron stores in nearly 50% of patients.

Hepcidin is iron regulatory hormone; it is synthesized mainly in hepatocytes. Hepcidin synthesis is increased by iron overload and decreased by anemia and hypoxia. Moreover, it is also induced by infection and inflammation.

Disturbance in hepcidin regulation has been reported as a possible mechanism causing iron overload in
As regard serum hepcidin, there was highly significant decrease in S. hepcidin level in group (A)CHC patients with in comparison to control group.

This agrees with Mohamed\textsuperscript{26} who found that Serum hepcidin was lower in chronic hepatitis C patients than in control group.

Also, our results were in agreement with Terrence\textsuperscript{20} who made a study on patients with CLD and healthy controls. They found that patients with cirrhosis had significantly lower hepcidin and compared with those without cirrhosis.

Pietrangelo\textsuperscript{29} reported a decrease in serum hepcidin along with increased serum ferritin in decompensated cirrhotic and the levels also correlated with the severity of the disease. Also This agrees with Girelli\textsuperscript{30} who reported lower serum hepcidin in chronic hepatitis C patients than in control group.

However our results did not agree with Fujita\textsuperscript{22} who found that there is no significant difference in hepcidin levels between chronic hepatitis C patients and control group, maybe due to low number of controls enrolled. Regarding to the improvement of serum hepcidin levels after 24 weeks of treatment with antiviral drugs, we found significant increase in serum hepcidin after therapy. This goes in agreement with Ismail\textsuperscript{25} who found That diminished level of serum hepcidin in CHC was fully reversible after successful eradication of HCV following therapy. Fujita\textsuperscript{22} also found that serum hepcidin levels were elevated after antiviral treatment.

In our study, serum ferritin and serum iron levels of patients were increased after 24 weeks with antiviral treatment compared to the base line. This goes in agreement with Bazeed\textsuperscript{23} who reported increase in ferritin and iron in CHC patients after antiviral therapy.

On the contrary, Fujita\textsuperscript{22} found that when the patients were assigned to SVR, they were recovered from iron overload status with reduction of serum ferritin level. This may be due to the lag of reduction of serum ferritin after initial improvement of serum hepcidin levels and also follow up of our patient after achievement of sustained virological response may be associated with normalization of serum ferritin levels.

**CONCLUSION**

From the current study we can conclude that chronic HCV is associated with diminished level of serum hepcidin, however this reduced level is fully reversible with antiviral therapy. Also the initial rise of serum hepcidin could be used as an indicator of patients response to therapy although we recommend a wider scale study (regarding patients numbers and duration) for a better understanding of the prognostic and monitoring role of hepcidin among chronic HCV patients on antiviral therapy.

**REFERENCES**


